Apath expands HCV contract screening sublicense with Southern Research Institute by expanding the current sublicense to include full virus screening systems.
Apath expands HCV technology portfolio by acquiring licensing rights to three new HCV technologies developed at The Rockefeller University.
Apath expands HCV technology portfolio by acquiring licensing rights to new HCV technologies developed by Dr. Jens Bukh and his colleagues at The University Copenhagen.
Our development strategies for clients involve providing them access to innovative anti-HCV development platforms and exceptional research and development tools. Below are links to five white papers describing some of our most requested research tools by our global licensees.
Our development solutions for clients encompass a harmonized approach of providing sublicensing opportunities to our extensive patent portfolio, assistance in implementing our anti-HCV technologies and access to our experienced virologists.